AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of 220.36 billion. The enterprise value is 247.90 billion.
| Market Cap | 220.36B |
| Enterprise Value | 247.90B |
Important Dates
The next estimated earnings date is Tuesday, July 29, 2025.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | Feb 20, 2025 |
Share Statistics
| Current Share Class | 1.55B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 28.35 and the forward PE ratio is 15.24.
| PE Ratio | 28.35 |
| Forward PE | 15.24 |
| PS Ratio | 4.01 |
| PB Ratio | 5.36 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.76 |
| P/OCF Ratio | 16.84 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.78, with an EV/FCF ratio of 22.23.
| EV / Earnings | 31.90 |
| EV / Sales | 4.32 |
| EV / EBITDA | 12.78 |
| EV / EBIT | 17.50 |
| EV / FCF | 22.23 |
Financial Position
The company has a current ratio of 0.90, with a Debt / Equity ratio of 0.77.
| Current Ratio | 0.90 |
| Quick Ratio | 0.69 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 1.70 |
| Debt / FCF | 2.84 |
| Interest Coverage | 10.16 |
Financial Efficiency
Return on equity (ROE) is 19.79% and return on invested capital (ROIC) is 11.73%.
| Return on Equity (ROE) | 19.79% |
| Return on Assets (ROA) | 8.16% |
| Return on Invested Capital (ROIC) | 11.73% |
| Return on Capital Employed (ROCE) | 17.65% |
| Revenue Per Employee | 583,054 |
| Profits Per Employee | 82,418 |
| Employee Count | 94,300 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.72 |
Taxes
In the past 12 months, AstraZeneca has paid 1.51 billion in taxes.
| Income Tax | 1.51B |
| Effective Tax Rate | 16.26% |
Stock Price Statistics
The stock price has decreased by -12.48% in the last 52 weeks. The beta is 0.17, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | -12.48% |
| 50-Day Moving Average | 140.84 |
| 200-Day Moving Average | 142.12 |
| Relative Strength Index (RSI) | 43.23 |
| Average Volume (20 Days) | 3,479 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of 54.98 billion and earned 7.77 billion in profits. Earnings per share was 4.97.
| Revenue | 54.98B |
| Gross Profit | 45.33B |
| Operating Income | 13.61B |
| Pretax Income | 9.29B |
| Net Income | 7.77B |
| EBITDA | 18.28B |
| EBIT | 13.61B |
| Earnings Per Share (EPS) | 4.97 |
Balance Sheet
The company has 5.40 billion in cash and 31.72 billion in debt, giving a net cash position of -26.32 billion.
| Cash & Cash Equivalents | 5.40B |
| Total Debt | 31.72B |
| Net Cash | -26.32B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 41.13B |
| Book Value Per Share | 26.48 |
| Working Capital | -2.99B |
Cash Flow
In the last 12 months, operating cash flow was 13.09 billion and capital expenditures -1.94 billion, giving a free cash flow of 11.15 billion.
| Operating Cash Flow | 13.09B |
| Capital Expenditures | -1.94B |
| Free Cash Flow | 11.15B |
| FCF Per Share | n/a |
Margins
Gross margin is 82.44%, with operating and profit margins of 24.75% and 14.14%.
| Gross Margin | 82.44% |
| Operating Margin | 24.75% |
| Pretax Margin | 16.90% |
| Profit Margin | 14.14% |
| EBITDA Margin | 33.24% |
| EBIT Margin | 24.75% |
| FCF Margin | 20.28% |
Dividends & Yields
This stock pays an annual dividend of 3.10, which amounts to a dividend yield of 2.12%.
| Dividend Per Share | 3.10 |
| Dividend Yield | 2.12% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 63.60% |
| Buyback Yield | -0.08% |
| Shareholder Yield | 2.04% |
| Earnings Yield | 3.53% |
| FCF Yield | 5.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.08 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.08 |
| Piotroski F-Score | 7 |